PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia
JACC: Basic to Translational Science · 2024-10 · 9 (10) · 1195-1210
DOI: 10.1016/j.jacbts.2024.06.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Basic to Translational Science, 2024-10. Verfasst von Carla Borràs und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación BBVA, Gobierno de Espana Ministerio de Universidades.
Abstract (Originalsprache)
We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies to restore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH) and to enhance the macrophage-specific reverse cholesterol transport pathway in mice. Analyses of macrophage-derived cholesterol distribution of plasma from FH patients revealed that low-density lipoprotein (LDL) particles contained less, and high-density lipoprotein particles contained more radiolabeled cholesterol after treatment with either PCSK9 inhibitor. PCSK9 antibodies facilitated the transfer of macrophage-derived cholesterol and LDL-derived cholesterol to feces exclusively in heterozygous LDL receptor-deficient mice expressing human APOB100. PCSK9 inhibitors act as positive regulators of the macrophage-specific reverse cholesterol transport pathway in individuals with heterozygous FH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
- Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain.
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Madrid, Spain.
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Rovira i Virgili University, IISPV, Reus, Spain.
- Institute of Biomedical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Barcelona, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Förderung
- Instituto de Salud Carlos III
- Fundación BBVA
- Gobierno de Espana Ministerio de Universidades
- Fundació la Marató de TV3
- Gobierno de España Ministerio de Ciencia e Innovación
Zitieren
APA
Borràs, C., Canyelles, M., Girona, J., Ibarretxe, D., Santos, D., Revilla, G., Llorente-Cortes, V., Rotllan, N., Kovanen, P. T., Jauhiainen, M., Lee-Rueckert, M., Masana, L., Arrieta, F., Martínez-Botas, J., Gómez-Coronado, D., Ribalta, J., Tondo, M., Blanco-Vaca, F., & Escolà-Gil, J. C. (2024). PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia. JACC: Basic to Translational Science, 9(10), 1195-1210. https://doi.org/10.1016/j.jacbts.2024.06.008
Vancouver
Borràs C, Canyelles M, Girona J, Ibarretxe D, Santos D, Revilla G, et al. PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia. JACC: Basic to Translational Science. 2024;9(10):1195-1210. doi:10.1016/j.jacbts.2024.06.008
BibTeX
@article{Borrs2024,
author = {Borràs, Carla and Canyelles, Marina and Girona, Josefa and Ibarretxe, Daiana and Santos, David and Revilla, Giovanna and Llorente-Cortes, Vicenta and Rotllan, Noemí and Kovanen, Petri T and Jauhiainen, Matti and Lee-Rueckert, Miriam and Masana, Luis and Arrieta, Francisco and Martínez-Botas, Javier and Gómez-Coronado, Diego and Ribalta, Josep and Tondo, Mireia and Blanco-Vaca, Francisco and Escolà-Gil, Joan Carles},
title = {PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia},
journal = {JACC: Basic to Translational Science},
year = {2024},
volume = {9},
number = {10},
pages = {1195--1210},
doi = {10.1016/j.jacbts.2024.06.008}
}
EUVIMED